Denali Therapeutics Inc (DNLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2017 | 06-2017 | 03-2017 | 12-2016 | 12-2015 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 0 | 0 | 0 | 39,853 | 30,740 |
| Marketable Securities | 0 | 0 | 0 | 138,478 | 0 |
| Other current assets | 0 | 0 | 0 | 3,624 | 2,690 |
| TOTAL | $0 | $0 | $0 | $181,955 | $33,430 |
| Non-Current Assets | |||||
| PPE Net | N/A | N/A | N/A | 16,850 | 3,280 |
| Investments And Advances | 0 | 0 | 0 | 72,580 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 1,270 | 80 |
| TOTAL | $N/A | $N/A | $N/A | $90,700 | $3,360 |
| Total Assets | $0 | $0 | $0 | $271,067 | $36,680 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 0 | 0 | 0 | 1,960 | 1,710 |
| Accrued Expenses | 0 | 0 | 0 | 3,850 | 600 |
| Other current liabilities | 0 | 0 | 0 | 3,290 | 1,160 |
| TOTAL | $0 | $0 | $0 | $9,106 | $3,480 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 0 | 0 | 7,440 | 520 |
| TOTAL | $N/A | $N/A | $N/A | $7,440 | $520 |
| Total Liabilities | $0 | $0 | $0 | $16,548 | $4,000 |
| Shareholders' Equity | |||||
| Common Shares | 0 | 0 | 0 | 340 | 170 |
| Retained earnings | 0 | 0 | 0 | -103,512 | -16,860 |
| Other shareholders' equity | 0 | 0 | 0 | 348,311 | 48,310 |
| TOTAL | $0 | $0 | $0 | $254,519 | $32,670 |
| Total Liabilities And Equity | $0 | $0 | $0 | $271,067 | $36,670 |